Solid Tumors with Specific Mutations

IDH 1/2 mutant
- 10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
- 10222: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors

CCNE1 amplification
- 10136: A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification

PTEN, PIK3CA
- * 10221: Phase III Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors
- ▼ 10131: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: breast, prostate, other solid tumors)

DNA repair; PI3K/AKT; RAS/RAF/MEK
- 10149: Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors
- ▼ 10217: A Phase Ib Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors (Expansion: germline or and somatic DDR aberrations; PIK3CA mutant; PTEN loss)
- * 10329: Phase I Sequential Trial of Agents Against DNA Repair (STAR) (Dose escalation: enriched for DDR aberrations; Expansion: Cohort A: BRCA1/2; Cohort B: DDR aberrations)

NF1, KEAP1, and LKB1
- 10220: A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

Loss of SETD2
- 10170: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

NUT fusion oncogene
- * 10295: A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma